Login to Your Account

Other News To Note

Wednesday, November 2, 2011

• Alnylam Pharmaceuticals Inc., of Cambridge, Mass., formed a collaboration with GlaxoSmithKline plc, of London, focused on the use of Alnylam's VaxiRNA technology to produce certain GSK vaccine products. VaxiRNA is an RNAi technology for the enhanced production of viruses used to manufacture vaccine products. The GSK collaboration is focused initially on influenza vaccine production in cell culture systems, with an option for applications in two additional vaccine products.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription